The main objectives of the Administrative Core (Core A) are to develop overarching collaborative initiatives and to provide the necessary coordination and prioritization of the available resources among the participating Research Projects and Reagent/Service Core (Core B). Core A will provide a forum through which the Project Directors and Core Leaders communicate openly and regularly. Activities that Core A will be coordinating include monthly Project Directors'meetings, monthly research conferences, annual research retreat, annual reports to the Advisory Committee, preparation, submission, renewal and monitoring of research protocols (animal, human and biosafety), and communication with internal and external funding agencies regarding budgetary matters. In close consultation with the Advisory Committee, Core A will play a central role in assessing the progress and productivity of this Program, resolve potential barriers and ensure that the entire program and each of its components are on the right track. Through these activities, the Core will serve to ensure cost-effectiveness, enhance program integration, accelerate scientific productivity, and maximize translational output.
The Administrative Core will play a central role in coordinating all the collaborative, administrative, budgetary, and compliance matters for this Program Project grant and in ensuring synergy. Integration and productivity. This will in turn contribute directly to the goals of this Program to understand the molecular tumorigenesis and discover novel therapies for bladder cancer.
|Zeng, Xingruo; Xu, Zhou; Gu, Jiayan et al. (2016) Induction of miR-137 by Isorhapontigenin (ISO) Directly Targets Sp1 Protein Translation and Mediates Its Anticancer Activity Both In Vitro and In Vivo. Mol Cancer Ther 15:512-22|
|Xu, Zhou; Zeng, Xingruo; Xu, Jiawei et al. (2016) Isorhapontigenin suppresses growth of patient-derived glioblastoma spheres through regulating miR-145/SOX2/cyclin D1 axis. Neuro Oncol 18:830-9|
|Zhou, Haiping; He, Feng; Mendelsohn, Cathy L et al. (2016) FGFR3b Extracellular Loop Mutation Lacks Tumorigenicity In Vivo but Collaborates with p53/pRB Deficiency to Induce High-grade Papillary Urothelial Carcinoma. Sci Rep 6:25596|
|Wang, Y; Xu, J; Gao, G et al. (2016) Tumor-suppressor NFÎºB2 p100 interacts with ERK2 and stabilizes PTEN mRNA via inhibition of miR-494. Oncogene 35:4080-90|
|Zhou, Haiping; Wang, Xing; Mo, Lan et al. (2016) Role of isoenzyme M2 of pyruvate kinase in urothelial tumorigenesis. Oncotarget 7:23947-60|
|Madka, Venkateshwar; Mohammed, Altaf; Li, Qian et al. (2016) Targeting mTOR and p53 Signaling Inhibits Muscle Invasive Bladder Cancer In Vivo. Cancer Prev Res (Phila) 9:53-62|
|Liu, Zhongbo; Yokoyama, Noriko N; Blair, Christopher A et al. (2016) High Sensitivity of an Ha-RAS Transgenic Model of Superficial Bladder Cancer to Metformin Is Associated with âˆ¼240-Fold Higher Drug Concentration in Urine than Serum. Mol Cancer Ther 15:430-8|
|Jiang, Guosong; Wu, Amy D; Huang, Chao et al. (2016) Isorhapontigenin (ISO) Inhibits Invasive Bladder Cancer Formation In Vivo and Human Bladder Cancer Invasion In Vitro by Targeting STAT1/FOXO1 Axis. Cancer Prev Res (Phila) 9:567-80|
|Wankel, Bret; Ouyang, Jiangyong; Guo, Xuemei et al. (2016) Sequential and compartmentalized action of Rabs, SNAREs, and MAL in the apical delivery of fusiform vesicles in urothelial umbrella cells. Mol Biol Cell 27:1621-34|
|Liang, Yuguang; Zhu, Junlan; Huang, Haishan et al. (2016) SESN2/sestrin 2 induction-mediated autophagy and inhibitory effect of isorhapontigenin (ISO) on human bladder cancers. Autophagy 12:1229-39|
Showing the most recent 10 out of 42 publications